TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39734743

Group type: EXPERIMENTAL
Intervention: Various agents including decitabine, cytarabine, daunorubicin, etoposide, venetoclax, and two experimental bromodomain and extraterminal (BET) inhibitors
Number of subjects: 1
Study: 39735169

Group type: EXPERIMENTAL
Intervention: Crisis response planning (CRP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 39735351

Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS) 2.0 mg b.i.d. (BOS-BOS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (BOS-PBO)
Number of subjects: 48
Study: 39735403

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 22
Study: 39735417

Group type: EXPERIMENTAL
Intervention: Teplizumab (CD3 monoclonal antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Otelixizumab (anti-CD3 monoclonal antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daclizumab (anti-CD25 monoclonal antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ladarixin (CXCR1/2 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reparixin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lantidra
Number of subjects: 0
Study: 39735942

Group type: EXPERIMENTAL
Intervention: Enhanced monitoring (ECG, Holter monitor, KardiaMobile device)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard monitoring (ECG and Holter monitor)
Number of subjects: 69
Study: 39735948

Group type: EXPERIMENTAL
Intervention: Panvascular disease (PVD)
Number of subjects: 2119

Group type: EXPERIMENTAL
Intervention: Quality of life (QOL)
Number of subjects: 2119

Group type: EXPERIMENTAL
Intervention: Exercise capacity
Number of subjects: 2119

Group type: EXPERIMENTAL
Intervention: Clinical outcomes
Number of subjects: 2119
Study: 39736112

Group type: EXPERIMENTAL
Intervention: Focused lung ultrasound (FLUS) performed by general practitioners (GPs) after a training program.
Number of subjects: 91
Study: 39736329

Group type: EXPERIMENTAL
Intervention: 1.5 g/kg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.8 g/kg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1.1 g/kg/day
Number of subjects: 30
Study: 39736452

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy plus radiotherapy (ICR)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Immunochemotherapy (IC) alone
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy plus radiotherapy (ICR) with definitive dose RT to primary tumor
Number of subjects: 702
Study: 39736544

Group type: EXPERIMENTAL
Intervention: Proton therapy (PRT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Photon radiotherapy (XRT)
Number of subjects: 160
Study: 39736611

Group type: EXPERIMENTAL
Intervention: BCG group
Number of subjects: 1564

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1564

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1564

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 1564

Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 1564
Study: 39736616

Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopy (FURS)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Mini Percutaneous Nephrolithotomy (Mini PCNL)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Number of subjects: 414
Study: 39736619

Group type: EXPERIMENTAL
Intervention: Developed questionnaire assessing perceived physical exertion
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Developed questionnaire
Number of subjects: 237
Study: 39736673

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation with load-adjustable gain factors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pressure Support Ventilation
Number of subjects: 0
Study: 39736740

Group type: EXPERIMENTAL
Intervention: Attractive targeted sugar baits (ATSBs) deployed in March 2022
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: Household survey and bed net usage
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: Factors associated with RDT positivity
Number of subjects: 2962
Study: 39736760

Group type: EXPERIMENTAL
Intervention: miRNA-7a-2-3p
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: miRNA-21-5p
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: miRNA-100-5p
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: miRNA-125b-5p
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: miRNA-200b-3p
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: miRNA-200b-5p
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: miRNA-7a-3p
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High baseline miRNA-7a2-3p
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High baseline miRNA-21-5p
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High baseline miRNA-200b-3p
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lower bleeding on probing (BOP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: miRNA-125b-2-3p
Number of subjects: 21
Study: 39736787

Group type: EXPERIMENTAL
Intervention: IBI110 monotherapy (0.01/0.1/0.3/1/3/10/20 mg/kg Q3W)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: IBI110 plus sintilimab (0.3/0.7/1.5/3/5/8/10 mg/kg Q3W + sintilimab 200 mg Q3W)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: IBI110 plus sintilimab and chemotherapy (RP2D 200 mg (3 mg/kg) Q3W) in sqNSCLC
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: IBI110 plus sintilimab and chemotherapy (RP2D 200 mg (3 mg/kg) Q3W) in GC
Number of subjects: 110
Study: 39736868

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with predictive low glucose suspend (SmartGuard)
Number of subjects: 31

Group type: COMPARATOR
Intervention: User initiated CGM (iscCGM)
Number of subjects: 31
Study: 39736874

Group type: EXPERIMENTAL
Intervention: Exposure to phthalate esters (DEHP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to DEHP metabolites (mono(2-carboxymethylhexyl) phthalate, mono-n-butyl phthalate, monoethylphthalate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular exercise
Number of subjects: 0
Study: 39737062

Group type: EXPERIMENTAL
Intervention: Infants born after the last lockdown (March 2020-May 2021)
Number of subjects: 1989

Group type: COMPARATOR
Intervention: Infants born before the first COVID-19 lockdown (April 2018-March 2020)
Number of subjects: 1989
Study: 39737148

Group type: EXPERIMENTAL
Intervention: Surgical navigation arm
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional arm
Number of subjects: 69

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 69
Study: 39737219

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg IV) + Tremelimumab (75 mg IV) on Day 1 q4 weeks for 4 cycles followed by Durvalumab q4 weeks until disease progression
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Number of subjects: 140
Study: 39737328

Group type: EXPERIMENTAL
Intervention: Live group music therapy session + standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 0
Study: 39737396

Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade), Cladribine, and Rituximab
Number of subjects: 0
Study: 39737542

Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo plus enzalutamide
Number of subjects: 116
Study: 39737577

Group type: EXPERIMENTAL
Intervention: Volitional contractions
Number of subjects: 27

Group type: COMPARATOR
Intervention: Involuntary contractions
Number of subjects: 27
Study: 39737579

Group type: EXPERIMENTAL
Intervention: Intraoral camera
Number of subjects: 508

Group type: COMPARATOR
Intervention: Smartphone
Number of subjects: 508
Study: 39737640

Group type: EXPERIMENTAL
Intervention: Tofacitinib (JAK inhibitor) for 16 weeks
Number of subjects: 10
Study: 39737816

Group type: EXPERIMENTAL
Intervention: Low-dose emicizumab prophylaxis (2.0-2.5 mg/kg every fortnight for two loading doses, then every 4 weeks) for 8 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-dose emicizumab prophylaxis
Number of subjects: 15
Study: 39737895

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 25
Study: 39737899

Group type: EXPERIMENTAL
Intervention: BPX-601 with rimiducid
Number of subjects: 33

Group type: COMPARATOR
Intervention: BPX-601 without rimiducid
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: BPX-601
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rimiducid
Number of subjects: 33
Study: 39738721

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 39738784

Group type: EXPERIMENTAL
Intervention: G2min scans
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: G1min scans
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: G45s scans
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: G10min scans
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: G30s scans
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All scan durations
Number of subjects: 38
Study: 39738864

Group type: EXPERIMENTAL
Intervention: Eccentric-based resistance exercise (10 × 10 repetitions of parallel back squats with a 4-s eccentric phase)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Eccentric-based resistance exercise
Number of subjects: 19
Study: 39738874

Group type: EXPERIMENTAL
Intervention: Staphylococcus epidermidis in severe AV (0.3%)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Staphylococcus caprae in mild AV (1.5%)
Number of subjects: 108
Study: 39738931

Group type: EXPERIMENTAL
Intervention: Orteronel (TAK-700)
Number of subjects: 10
Study: 39738982

Group type: EXPERIMENTAL
Intervention: Mobility Assistive Technologies (MAT) - Wheelchair users
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Mobility Assistive Technologies (MAT) - Walking aid users
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Mobility Assistive Technologies (MAT) - No MAT users
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L Mobility Item
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 607
Study: 39739120

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Salicylic acid
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 48
Study: 39739195

Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg
Number of subjects: 3155

Group type: EXPERIMENTAL
Intervention: Fezolinetant 45 mg
Number of subjects: 3155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3155

Group type: EXPERIMENTAL
Intervention: Fezolinetant (both doses)
Number of subjects: 3155
Study: 39739628

Group type: EXPERIMENTAL
Intervention: RO5459072 (100 mg b.i.d., 200 mg daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 39739679

Group type: EXPERIMENTAL
Intervention: DILEU (2 grams daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 34

Group type: COMPARATOR
Intervention: LEU
Number of subjects: 34
Study: 39739762

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g twice a day for 14 days)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 39739826

Group type: EXPERIMENTAL
Intervention: DIMS spectacles (n = 78)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 0.01% atropine (n = 78)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Usual care (n = 78)
Number of subjects: 234
Study: 39739907

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice-daily
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice-daily
Number of subjects: 489
Study: 39739967

Group type: EXPERIMENTAL
Intervention: Visual Analog Scales (VAS) for anxiety
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Visual Analog Scales (VAS) for mood
Number of subjects: 182

Group type: COMPARATOR
Intervention: HADS (Hospital Anxiety and Depression Scale)
Number of subjects: 182
Study: 39739975

Group type: EXPERIMENTAL
Intervention: Immunonutrition (IMN) for five days before and seven days after elective surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine nutritional care before the operation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 39739976

Group type: EXPERIMENTAL
Intervention: Upamostat (LH011) at doses of 100, 200, 400, or 600 mg daily combined with gemcitabine (1000 mg/m2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Upamostat (LH011) at doses of 100 to 600 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Upamostat (LH011)
Number of subjects: 17
Study: 39739990

Group type: EXPERIMENTAL
Intervention: LOW dose prolonged-release tacrolimus (TAC) with other antihypertensive therapy (OAHT)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Standard dose prolonged-release tacrolimus (TAC) with or without ACEi/ARB
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: LOW dose prolonged-release tacrolimus (TAC) with renin-angiotensin system (RAS) blockade
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: LOW dose prolonged-release tacrolimus (TAC) without RAS blockade
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Overall patient survival
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Graft function, blood pressure (BP), and proteinuria
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Use of ACEi/ARB in patients randomized initially to OAHT
Number of subjects: 281
Study: 39740193

Group type: EXPERIMENTAL
Intervention: Spousal relationship quality and social support
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Maternal age and paternal occupation as moderating factors
Number of subjects: 352
Study: 39740215

Group type: EXPERIMENTAL
Intervention: Complete Lifestyle Medicine Intervention Program-Ontario (CLIP-ON) consisting of 22 weeks of weekly group sessions and monthly individual consultations with physicians, health coaches, kinesiologists, and registered dieticians.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CLIP-ON program
Number of subjects: 10
Study: 39740313

Group type: EXPERIMENTAL
Intervention: Cabozantinib at 60 mg/day (recommended dose)
Number of subjects: 679
Study: 39740340

Group type: EXPERIMENTAL
Intervention: ChatGPT
Number of subjects: 122

Group type: COMPARATOR
Intervention: Manual surveillance
Number of subjects: 122
Study: 39740666

Group type: EXPERIMENTAL
Intervention: Vosoritide 15 μg/kg daily
Number of subjects: 119
Study: 39740667

Group type: EXPERIMENTAL
Intervention: TP-102 phage cocktail
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TP-102 + standard of care (SOC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo + SOC
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TP-102
Number of subjects: 19
Study: 39740941

Group type: EXPERIMENTAL
Intervention: WJ-UC-MSC solution
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 39740942

Group type: EXPERIMENTAL
Intervention: Fish oil (2.4 g/day, 55% EPA and 37% DHA)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (3200 IU/day)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Fish oil and vitamin D trials
Number of subjects: 4000
Study: 39740945

Group type: EXPERIMENTAL
Intervention: Creative Arts and Psychomotor Therapies (CAPTs) intervention
Number of subjects: 17
Study: 39740951

Group type: EXPERIMENTAL
Intervention: PIT programme (pharmacist reconciliation of medications and structured handoff)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care (standard practices)
Number of subjects: 14
Study: 39740955

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 287

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 287
Study: 39740957

Group type: EXPERIMENTAL
Intervention: 1% chloroprocaine
Number of subjects: 110

Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 110
Study: 39741233

Group type: EXPERIMENTAL
Intervention: CKI combined with first-line treatment (FOLFOX/FOLFIRI/CAPEOX ± cetuximab/bevacizumab)
Number of subjects: 320

Group type: COMPARATOR
Intervention: First-line treatment (FOLFOX/FOLFIRI/CAPEOX ± cetuximab/bevacizumab)
Number of subjects: 320
Study: 39741317

Group type: EXPERIMENTAL
Intervention: Palliative sedation
Number of subjects: 78
Study: 39741323

Group type: EXPERIMENTAL
Intervention: EMDR + active-MtCS
Number of subjects: 96

Group type: COMPARATOR
Intervention: EMDR + sham-MtCS
Number of subjects: 96

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 96
Study: 39741356

Group type: EXPERIMENTAL
Intervention: ActiveGames4Change intervention
Number of subjects: 50
Study: 39741695

Group type: EXPERIMENTAL
Intervention: Atezolizumab/bevacizumab
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Patient expectations
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Patient-physician concordance
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Consultation length
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Discussion of life expectancy
Number of subjects: 205
Study: 39742012

Group type: EXPERIMENTAL
Intervention: Modified Remote Ischemic Preconditioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 39742013

Group type: EXPERIMENTAL
Intervention: Stress Ball intervention, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 39742454

Group type: EXPERIMENTAL
Intervention: SMS text message reminder
Number of subjects: 24388

Group type: COMPARATOR
Intervention: Standard postal reminder letter
Number of subjects: 24388

Group type: EXPERIMENTAL
Intervention: SMS text message reminder with recovery strategy (2nd reminder by letter)
Number of subjects: 24388
Study: 39742483

Group type: EXPERIMENTAL
Intervention: Highly trained athletes (ATHL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary normal weight (LEAN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sedentary overweight-to-obese (OVWE)
Number of subjects: 0
Study: 39742565

Group type: EXPERIMENTAL
Intervention: IGRA+ pre-treatment (n=15)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: IGRA+ post-treatment (n=15)
Number of subjects: 35

Group type: COMPARATOR
Intervention: IGRA- controls (n=5)
Number of subjects: 35
Study: 39742855

Group type: EXPERIMENTAL
Intervention: Video-call format
Number of subjects: 498

Group type: COMPARATOR
Intervention: In-person format
Number of subjects: 498
Study: 39742894

Group type: EXPERIMENTAL
Intervention: FIBRO-Out
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FIBRO-On
Number of subjects: 120

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 120
Study: 39742913

Group type: COMPARATOR
Intervention: HFNC at 40 L/min
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HFNC at 60 L/min
Number of subjects: 169
Study: 39743016

Group type: EXPERIMENTAL
Intervention: InBloom app (asynchronously delivered intervention)
Number of subjects: 152

Group type: COMPARATOR
Intervention: ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) intervention (synchronously delivered in-person intervention)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Historical control subjects from the largest ROSE trial
Number of subjects: 152

Group type: COMPARATOR
Intervention: Electronic Health Record (EHR) data on concurrent patients not offered InBloom or ROSE
Number of subjects: 152
Study: 39743172

Group type: EXPERIMENTAL
Intervention: Beta-blockers (BB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No beta-blockers (no BB)
Number of subjects: 200
Study: 39743240

Group type: EXPERIMENTAL
Intervention: Exergaming
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Medical yoga
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 39743326

Group type: EXPERIMENTAL
Intervention: EOLD-CAD scale
Number of subjects: 611
Study: 39743436

Group type: EXPERIMENTAL
Intervention: Abatacept (10, 20, or 25 mg/kg) administered intravenously on Days 1, 5±2, and 14±2
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Abatacept (10, 20, or 25 mg/kg) with concomitant ruxolitinib and corticosteroids
Number of subjects: 21
Study: 39743478

Group type: EXPERIMENTAL
Intervention: First-line oxaliplatin-based chemotherapy
Number of subjects: 40
Study: 39743618

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-L1 blockade Adebrelimab (two cycles)
Number of subjects: 23
Study: 39744036

Group type: EXPERIMENTAL
Intervention: rTMS and hedonic olfactory stimulations
Number of subjects: 80

Group type: COMPARATOR
Intervention: rTMS alone
Number of subjects: 80
Study: 39744082

Group type: EXPERIMENTAL
Intervention: Pair condition (participants with a partner)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Alone condition (participants alone)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (healthy controls) in Pair condition
Number of subjects: 125
Study: 39744206

Group type: EXPERIMENTAL
Intervention: 16s ribosomal RNA PCR
Number of subjects: 100

Group type: COMPARATOR
Intervention: Valve culture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Molecular test combined with histopathological analysis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Molecular test
Number of subjects: 100
Study: 39744353

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1830

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1830
Study: 39744679

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39744745

Group type: EXPERIMENTAL
Intervention: Injection of 3 ml 0.1% ropivacaine with 0.3 μg ml-1 sufentanil through the Tuohy needle followed by a 15 ml loading dose over 30 seconds
Number of subjects: 200

Group type: COMPARATOR
Intervention: Injection of the same ropivacaine/sufentanil mixture through a single end-hole epidural catheter
Number of subjects: 200
Study: 39744837

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 352